Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Cash & Equivalents: 2010-2025

Historic Cash & Equivalents for Heron Therapeutics (HRTX) over the last 13 years, with Sep 2025 value amounting to $43.1 million.

  • Heron Therapeutics' Cash & Equivalents rose 67.31% to $43.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.1 million, marking a year-over-year increase of 67.31%. This contributed to the annual value of $25.8 million for FY2024, which is 10.03% down from last year.
  • Per Heron Therapeutics' latest filing, its Cash & Equivalents stood at $43.1 million for Q3 2025, which was up 160.77% from $16.5 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Cash & Equivalents ranged from a high of $191.2 million in Q2 2021 and a low of $13.5 million during Q2 2023.
  • For the 3-year period, Heron Therapeutics' Cash & Equivalents averaged around $24.8 million, with its median value being $25.7 million (2024).
  • As far as peak fluctuations go, Heron Therapeutics' Cash & Equivalents soared by 136.81% in 2021, and later tumbled by 83.03% in 2022.
  • Heron Therapeutics' Cash & Equivalents (Quarterly) stood at $90.5 million in 2021, then crashed by 83.03% to $15.4 million in 2022, then spiked by 86.65% to $28.7 million in 2023, then decreased by 10.03% to $25.8 million in 2024, then surged by 67.31% to $43.1 million in 2025.
  • Its Cash & Equivalents stands at $43.1 million for Q3 2025, versus $16.5 million for Q2 2025 and $19.3 million for Q1 2025.